In a report published Monday, Jefferies reiterated its Hold rating on Covance CVD, and raised its price target from $52.00 to $68.00.
Jefferies noted, “The call was positive, with much of the focus on Central Lab and the outlook there, followed by Clinical. Bookings support continued growth, and margins appear sustainable barring cancellations or an uncharacteristic, aggressive strategic deal. Early Dev's underperformance and low visibility doesn't drag growth nearly as much now. The catch: the market clearly saw this coming.”
Covance closed on Friday at $67.61.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in